Medline faces securities fraud probe after stock drops 7% and 13% over manufacturing issues.

Medline Inc. is under investigation by Bleichmar Fonti & Auld LLP for potential securities fraud related to misleading statements about its manufacturing and product quality. The company's stock fell 7% on June 2, 2026, after the FDA issued a warning about significant violations in manufacturing practices. A further 13% drop occurred on August 5, 2026, following Medline's admission that remediation efforts impacted earnings. Investors who suffered losses are encouraged to contact the law firm for possible legal action.

Following the recent legal notice to Medline investors about potential securities fraud, MDLN shares continue to face pressure. On Pluang, Medline Inc. Class A Common Stock trades at USD 39.97, down 2.30% for the day as of Nov 11, 2026 18:21 WIB. The stock remains below its 52-week high of USD 49.99, reflecting ongoing market caution around the company.